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OBJECTIVE — To evaluate in impaired fasting glucose (IFG) the relative importance of
increases in waist circumference and weight on progression to type 2 diabetes.
RESEARCHDESIGNANDMETHODS — The9-yearincidenceofdiabeteswasstudied
in 979 men and women with baseline IFG, from the Data from an Epidemiological Study on the
Insulin Resistance Syndrome (DESIR) cohort.
RESULTS — Increases in both waist circumference and weight were signiﬁcantly associated
with diabetes incidence. Standardized odds ratios (95% CI) were 1.79 (1.45–2.21) and 1.86
(1.51–2.30), respectively, after controlling for baseline risk factors. The impact of waist circum-
ference increase was greater for BMI 25 kg/m
2 (2.40 [1.63–3.52]) than for BMI 25 kg/m
2
(1.66 [1.28–2.16]) and persisted after adjusting for concurrent changes in either insulinemia or
the homeostasis model assessment of insulin resistance index. Weight change had a similar
impact in both BMI groups.
CONCLUSIONS — InindividualswithIFG,itisimportanttomonitorandpreventincreases
in waist circumference, in particular for those with BMI 25 kg/m
2.
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I
ndividuals with impaired fasting glucose
(IFG) are at high risk for type 2 diabetes
(1,2). Although visceral adiposity and
waist circumference are strong risk factors
for type 2 diabetes (3), the consequence of
an increase in waist circumference among
individuals with IFG at baseline has not
been fully investigated, in particular in
those who are not overweight or obese at
baseline (4,5). This report investigates the
relativeimportanceofincreasesinwaistcir-
cumference and weight on progression to
diabetes in individuals with baseline IFG,
according to baseline BMI strata.
RESEARCH DESIGN AND
METHODS— We studied men and
women aged 30–64 years, who partici-
pated in the Data from an Epidemiologi-
cal Study on the Insulin Resistance
Syndrome (DESIR) cohort and who had
IFG at baseline (fasting plasma glucose
5.6–6.9 mmol/l). DESIR is a 9-year fol-
low-up study that aimed to clarify the de-
velopment of the insulin resistance
syndromeandtype2diabetes(6).Allpar-
ticipantssignedaninformedconsent,and
the protocol was approved by an ethics
committee.
Incident cases of diabetes had fasting
plasma glucose 7.0 mmol/l or treated
diabetes at one of the three yearly fol-
low-up examinations. The average varia-
tion per year in waist circumference and
weight was deﬁned as the difference be-
tween the visit when diabetes was
screened and the baseline visit divided
by the number of years of follow-up. A
total of 674 men and 305 women were
studied.
All analyses used R version 2.10.0
(Free Software Foundation, Boston, MA),
and a two-sided P  0.05 was considered
statistically signiﬁcant. Homeostasis
model assessment of insulin resistance
(HOMA2-IR) was computed using soft-
ware downloaded at http://www.dtu.ox.
ac.uk. Insulin, glucose, and HOMA2-IR
values were log transformed before anal-
ysis. We used logistic models for incident
diabetestoevaluatestandardizedoddsra-
tios with Wald 95% CIs, conditioned on
baseline BMI  and 25 kg/m
2, adjusted
for sex, family history of diabetes, base-
line age, current smoking, physical activ-
ity, fasting glucose, and hypertension
(systolic/diastolic blood pressures 140/
90 mmHg or treated for hypertension).
We tested for interactions between base-
lineBMIcategorieswithincreasesinwaist
circumference and weight on incident
diabetes.
RESULTS— There were 142 cases of
incident diabetes after 9 years of follow-
up. Individuals who became diabetic had
a greater increase over follow-up in both
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Service Endocrinologie, Center Hospitalier Universitaire de Rennes, Universite ´ Rennes, Rennes,
France, Institut National de la Sante ´ et de la Recherche Me ´dicale (INSERM) U625, Rennes, France; the
2De ´partement d’Endocrinologie, Diabe ´tologie et Nutrition, Assistance Publique-Ho ˆpitaux de Paris,
Ho ˆpital Bichat, Universite ´ Paris, Diderot, Paris, France, INSERM U695, Paris, France; the
3Service
d’Endocrinologie-Diabe ´tologie-Nutrition,CentreHospitalierUniversitaired’Angers,Universite ´ d’Angers,
Angers, France; the
4Centre de recherche en E ´pide ´miologie et Sante ´ des Populations, Epidemiology of
Diabetes, Obesity, and Chronic Kidney Disease Over the Life Course, INSERM, Villejuif, France; the
5Universite ´ Paris-Sud, Villejuif, France; and the
6Institut Inter Re ´gional pour la Sante, La Riche, France.
Corresponding author: F. Bonnet, fabrice.bonnet@chu-rennes.fr.
Received 24 February 2010 and accepted 3 May 2010. Published ahead of print at http://care.
diabetesjournals.org on 18 May 2010. DOI: 10.2337/dc10-0368.
*Members of the DESIR Study Group can be found in the online appendix at http://care.diabetesjournals.
org/cgi/content/full/dc10–0368/DC1.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
BRIEF REPORT
1850 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.orgwaist circumference and weight than
those who did not progress (online ap-
pendix Table 1, available at http://care.
diabetesjournals.org/cgi/content/full/dc10-
0368/DC1).
Changes in waist circumference and
weight were signiﬁcantly associated with
incident type 2 diabetes in multivariate
analysis,inbothBMIcategories(Table1).
The signiﬁcant impact of change in either
waist circumference or weight did not
vary by age at baseline (aged  or 50
years). There was an interaction between
BMI category and the effect of waist in-
crease for progression to diabetes, with a
larger impact in participants with BMI
25 kg/m
2 than in those with BMI 25
kg/m
2 (P for interaction  0.049).
An increase in waist circumference
remained signiﬁcantly associated with
progression to type 2 diabetes after con-
trolling for concurrent changes in either
insulinemia or the HOMA2-IR index, ir-
respectiveofbaselineBMIcategory(Table
1).Incontrast,theeffectofweightchange
was no longer signiﬁcant after controlling
for variations in either insulinemia or the
HOMA2-IR index in those with BMI 25
kg/m
2.
CONCLUSIONS — The main ﬁnd-
ingofthisstudyisthatanincreaseinwaist
circumference is a major risk factor for
type 2 diabetes in individuals with IFG,
irrespectiveofbaselineBMI.Inthosewith
BMI 25 kg/m
2, an increase in waist cir-
cumference appears to be a stronger risk
marker for progression to type 2 diabetes
than weight gain. This is in agreement
with a previous report that found greater
risk for diabetes in U.S. men who in-
creased their waist circumference (7);
however, these authors did not speciﬁ-
cally assess risk in IFG (7).
To our knowledge, this study is the
ﬁrst to assess the impact of waist increase
for progression to diabetes in the absence
of excessive weight at baseline. Previous
studies assessing risk factors for diabetes
in either the general population or in IFG
subjects did not perform analyses accord-
ing to BMI strata (4,5).
Our ﬁndings suggest the potential
value of monitoring waist circumference
over time in IFG. Waist circumference
probably reﬂects more accurately visceral
fat in leaner subjects because of the thin-
ner subcutaneous abdominal depot (8).
Another explanation may be that individ-
uals with IFG and prone to develop overt
diabetes tend to gain visceral fat more se-
lectively than subcutaneous fat, com-
pared with those who remained
nondiabetic. This could be sustained by
defects in adipogenesis and/or speciﬁci-
ties in adipose tissue morphology, inde-
pendently of body fat level, as recently
suggested (9). However, this hypothesis
cannot be demonstrated in the present
study. The effect of an increase in waist
circumference on the progression to dia-
betes was independent, at least partly, of
concomitant variations in insulinemia or
the HOMA2-IR index, suggesting addi-
tionalmechanismslinkingabdominalad-
iposity and -cell function (10).
Impaired -cell function is consid-
ered an important characteristic in indi-
viduals with IFG (11), and reduced
insulin secretion has been shown to be a
prominent mechanism leading to diabe-
tes in lean individuals (12,13). We spec-
ulate that an increase in waist
circumference may induce further alter-
ations in insulin secretion beyond that in-
herent in worsening insulin resistance.
Potential mechanisms may involve -cell
lipotoxicity through enhanced free fatty
acid release from adipose tissue (14).
Limitations of the present study in-
clude the absence of gold-standard mea-
sures of insulin sensitivity such as the
euglycemic–hyperinsulinemic clamp;
strengths are the large cohort with a low
prevalence of obesity and a long follow-
up. In conclusion, our results emphasize
the importance of monitoring and pre-
venting increases in waist circumference
in individuals with IFG, in particular in
those with BMI 25 kg/m
2.
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Table 1—Odds ratios (95% CI) for 9-year incident diabetes, per 1 SD change in waist circumference and weight in IFG: the DESIR study
All IFG participants BMI 25 kg/m
2 BMI 25 kg/m
2
n  979 n  433 n  546
Odds ratio
(95% CI) P
Odds ratio
(95% CI)* P
Odds ratio
(95% CI) P
Univariate
Change in waist circumference 1.69 (1.41–2.03) 0.0001 2.48 (1.73–3.55) 0.0001 1.48 (1.20–1.84) 0.0003
Change in weight 1.83 (1.53–2.19) 0.0001 1.86 (1.35–2.55) 0.0001 1.85 (1.48–2.32) 0.0001
Model 1
Change in waist circumference 1.79 (1.45–2.21) 0.0001 2.40 (1.63–3.52) 0.0001 1.66 (1.28–2.16) 0.0002
Change in weight 1.86 (1.51–2.30) 0.0001 1.92 (1.32–2.79) 0.0006 1.96 (1.50–2.55) 0.0001
Model 2
Change in waist circumference 1.65 (1.30–2.09) 0.0001 1.82 (1.21–2.75) 0.004 1.66 (1.22–2.24) 0.001
Change in weight 1.67 (1.30–2.15) 0.0001 1.20 (0.77–1.88) 0.4 1.97 (1.44–2.69) 0.0001
Model 3
Change in waist circumference 1.52 (1.18–1.96) 0.001 1.82 (1.18–2.80) 0.007 1.49 (1.08–2.06) 0.01
Change in weight 1.48 (1.13–1.95) 0.005 1.04 (0.64–1.70) 0.9 1.79 (1.29–2.50) 0.0006
Model1adjustedforsex,familyhistoryofdiabetes,andbaselineage,currentsmoking,physicalactivity,fastingglucose,andhypertension.Model2model1
change in fasting insulinemia. Model 3  model 1  change in HOMA2-IR. *SDs for the standardization of the odds ratios in all IFG participants, BMI 25 kg/m
2
group, and BMI 25 kg/m
2 group were, respectively, 0.78, 0.74, and 0.82 cm/year for change in waist circumference and 0.71, 0.62, and 0.77 kg/year for change
in weight.
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